Loading clinical trials...
Loading clinical trials...
A Prospective, Multicenter, Single-Arm Phase II Study of Serplulimab Combined With Oncolytic Virus H101, Short-Course Radiotherapy, and XELOX Chemotherapy as Total Neoadjuvant Therapy for Locally Advanced Rectal Cancer (cT1-3N0M0)
Conditions
Interventions
Serplulimab
Oncolytic Virus H101
+2 more
Locations
1
China
Chongqing University Cancer Hospital
Chongqing, Chongqing Municipality, China
Start Date
May 1, 2026
Primary Completion Date
December 31, 2028
Completion Date
December 31, 2028
Last Updated
April 22, 2026
NCT07541924
NCT04703101
NCT06696768
NCT06662786
NCT06663319
NCT05239741
Lead Sponsor
Chongqing University Cancer Hospital
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions